StocksFundsScreenerSectorsWatchlists
PACB

PACB - Pacific Biosciences of California Stock Price, Fair Value and News

3.15USD-0.23 (-6.80%)Delayed as of 12 Apr 2024, 03:04 pm ET

Market Summary

PACB
USD3.15-0.23
Delayedas of 12 Apr 2024, 03:04 pm
-6.80%

PACB Alerts

  • 1 major insider buys recently.

PACB Stock Price

View Fullscreen

PACB RSI Chart

PACB Valuation

Market Cap

905.7M

Price/Earnings (Trailing)

-2.95

Price/Sales (Trailing)

4.52

EV/EBITDA

-2.48

Price/Free Cashflow

-3.38

PACB Price/Sales (Trailing)

PACB Profitability

Operating Margin

26.32%

EBT Margin

-158.67%

Return on Equity

-43.74%

Return on Assets

-17.57%

Free Cashflow Yield

-29.59%

PACB Fundamentals

PACB Revenue

Revenue (TTM)

200.5M

Rev. Growth (Yr)

113.35%

Rev. Growth (Qtr)

4.79%

PACB Earnings

Earnings (TTM)

-306.7M

Earnings Growth (Yr)

2.8%

Earnings Growth (Qtr)

-22.65%

Breaking Down PACB Revenue

52 Week Range

3.1414.55
(Low)(High)

Last 7 days

1.5%

Last 30 days

-15.7%

Last 90 days

-49.6%

Trailing 12 Months

-68.7%

How does PACB drawdown profile look like?

PACB Financial Health

Current Ratio

7.81

Debt/Equity

0

Debt/Cashflow

-101.04

PACB Investor Care

Shares Dilution (1Y)

8.45%

Diluted EPS (TTM)

-1.21

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023134.0M146.1M169.5M200.5M
2022134.7M139.5M137.0M128.3M
202192.3M105.8M121.6M130.5M
202090.1M82.5M79.7M78.9M
201975.7M78.7M82.5M90.9M
201887.9M89.4M84.0M78.6M
201796.5M95.8M94.3M93.5M
201694.3M90.1M101.3M90.7M
201566.6M80.1M73.4M92.8M
201434.2M39.6M52.8M60.6M
201321.5M20.3M24.9M28.2M
201243.6M40.3M32.5M26.0M
20119.7M17.8M25.8M33.9M
20100648.0K1.2M1.7M
2009000135.0K

Tracking the Latest Insider Buys and Sells of Pacific Biosciences of California

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 15, 2024
ordonez kathy
acquired
1,038,680
2.8723
361,621
-
Mar 06, 2024
meline david w
bought
176,160
4.404
40,000
-
Mar 04, 2024
farmer michele
sold
-14,457
4.871
-2,968
see remarks
Mar 04, 2024
van oene mark
sold
-44,745
4.871
-9,186
see remarks
Mar 04, 2024
henry christian o
sold
-69,056
4.871
-14,177
see remarks
Mar 04, 2024
kim susan g.
sold
-25,694
4.871
-5,275
see remarks
Mar 01, 2024
mohr marshall
acquired
111,250
4.45
25,000
-
Feb 22, 2024
eidel jeff
acquired
-
-
461,538
see remarks
Feb 22, 2024
farmer michele
acquired
-
-
115,384
see remarks
Feb 22, 2024
van oene mark
acquired
-
-
798,076
see remarks

1–10 of 50

Which funds bought or sold PACB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 10, 2024
Green Alpha Advisors, LLC
added
20.54
-219,176
187,301
0.14%
Apr 09, 2024
Nalls Sherbakoff Group, LLC
unchanged
-
50.00
334
-%
Apr 08, 2024
TOMPKINS FINANCIAL CORP
new
-
469
469
-%
Apr 05, 2024
GAMMA Investing LLC
reduced
-89.41
-5,948
386
-%
Apr 05, 2024
CWM, LLC
reduced
-84.74
-2,000
-
-%
Apr 05, 2024
LOS ANGELES CAPITAL MANAGEMENT LLC
unchanged
-
-99,136
61,346
-%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
added
264
1,752
2,286
-%
Mar 14, 2024
ABLES, IANNONE, MOORE & ASSOCIATES, INC.
new
-
2,747
2,747
-%
Mar 11, 2024
VANGUARD GROUP INC
added
15.1
68,461,300
262,806,000
0.01%
Mar 05, 2024
Fisher Asset Management, LLC
added
0.13
80,834
539,098
-%

1–10 of 41

Are Funds Buying or Selling PACB?

Are funds buying PACB calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PACB
No. of Funds

Unveiling Pacific Biosciences of California's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
madrone capital partners, llc
6.6%
17,591,915
SC 13G/A
Feb 12, 2024
nikko asset management americas, inc.
4.93%
13,200,375
SC 13G/A
Feb 09, 2024
jackson square partners, llc
3.63%
9,704,766
SC 13G/A
Feb 05, 2024
sumitomo mitsui trust holdings, inc.
4.93%
13,200,375
SC 13G/A
Jan 29, 2024
ark investment management llc
12.90%
34,504,273
SC 13G/A
Jan 24, 2024
blackrock inc.
9.2%
24,642,666
SC 13G/A
Jan 10, 2024
vanguard group inc
10.02%
26,789,499
SC 13G/A
Feb 13, 2023
capital international investors
2.7%
6,099,681
SC 13G/A
Feb 13, 2023
madrone capital partners, llc
7.3%
16,415,933
SC 13G/A
Feb 10, 2023
nikko asset management americas, inc.
6.26%
14,166,193
SC 13G/A

Recent SEC filings of Pacific Biosciences of California

View All Filings
Date Filed Form Type Document
Apr 11, 2024
POSASR
POSASR
Apr 11, 2024
POSASR
POSASR
Apr 11, 2024
POSASR
POSASR
Mar 19, 2024
4
Insider Trading
Mar 06, 2024
4
Insider Trading
Mar 06, 2024
4
Insider Trading
Mar 06, 2024
4
Insider Trading
Mar 06, 2024
4
Insider Trading
Mar 06, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading

Peers (Alternatives to Pacific Biosciences of California)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
193.3B
40.1B
-7.74% 9.17%
33.78
4.82
-8.12% -17.45%
69.5B
19.5B
1.13% -5.26%
55.32
3.56
4.02% -22.04%
24.4B
3.9B
4.50% -2.28%
54.79
6.31
3.42% 23.09%
21.4B
14.8B
-1.84% -1.34%
8.05
1.44
2.12% 209.17%
MID-CAP
9.2B
12.3B
-3.51% -12.61%
22.18
0.75
-2.44% -22.68%
9.2B
3.5B
-2.27% 17.56%
32.29
2.63
4.97% 18.89%
9.1B
2.7B
-7.47% -34.56%
-14.3
3.41
-4.68% 82.43%
6.6B
4.0B
-4.70% -20.93%
-49.38
1.68
1.10% 85.84%
3.5B
366.4M
0.09% 23.27%
-569.11
9.43
33.86% 89.83%
2.3B
6.6B
-4.53% -3.52%
11.91
0.35
2.78% -0.87%
SMALL-CAP
1.3B
3.2B
-7.20% -16.80%
-1.97
0.42
7.73% -1066.14%
380.3M
166.7M
-0.70% -5.95%
-4.6
2.28
6.67% -456.34%
272.4M
324.0M
24.04% -26.14%
-1.42
0.84
-3.19% -337.41%
53.7M
52.3M
-9.88% -51.41%
-2.87
1.03
17.61% 19.28%
4.1M
3.7M
-7.69% 310.53%
-0.33
1.09
5.77% 8.23%

Pacific Biosciences of California News

Latest updates
Defense World33 hours ago
Zacks Investment Research03 Apr 202402:01 pm
Yahoo Finance16 Feb 202408:00 am

Pacific Biosciences of California Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue4.8%58,357,00055,691,00047,573,00038,900,00027,353,00032,311,00035,467,00033,173,00036,019,00034,887,00030,610,00028,997,00027,136,00019,082,00017,077,00015,598,00027,930,00021,915,00024,621,00016,425,00019,526,000
Cost Of Revenue29.1%48,786,00037,789,00032,027,00029,139,00022,213,00018,764,00019,274,00019,018,00019,253,00019,523,00016,857,00016,020,000---------
Gross Profit-46.5%9,571,00017,902,00015,546,0009,761,0005,140,00013,547,00016,193,00014,155,00016,766,00015,364,00013,753,00012,977,00011,401,0007,064,0006,613,0007,488,00012,932,0006,914,0009,613,0005,117,0005,746,000
Operating Expenses-3.3%97,119,000100,394,00088,721,000101,013,00092,224,00088,167,00084,162,00091,678,00081,442,00089,840,00051,326,00046,687,00035,378,00031,239,00030,137,00040,197,00030,849,00035,028,00033,993,00035,251,00036,369,000
  S&GA Expenses5.9%45,996,00043,431,00040,573,00039,818,00045,003,00036,795,00039,252,00039,804,00037,319,50031,606,00029,060,00026,139,00017,953,00014,772,00015,127,00024,947,00016,576,00020,066,00019,083,00019,766,00020,106,000
  R&D Expenses-6.3%44,544,00047,514,00046,173,00048,939,00042,623,00047,092,00050,348,00052,937,00042,576,50027,508,00022,266,00020,548,00017,425,00016,467,00015,010,00015,250,00014,273,00014,962,00014,910,00015,485,00016,263,000
EBITDA Margin16.0%-1.46-1.74-2.01-2.21-2.26-2.00-1.98-1.88-1.950.370.390.41---------
Interest Expenses-0.5%3,571,0003,588,0003,554,0003,630,0003,648,0003,664,0003,681,0003,697,0003,479,0003,673,0003,589,0001,789,000---267,000678,000664,000644,000625,000628,000
Income Taxes93.3%-718,000-10,706,000--------94,824,000-----------
Earnings Before Taxes-6.7%-82,736,000-77,575,000-69,833,000-88,015,000-84,384,000-76,971,000-71,394,000-81,499,000-68,154,000-78,282,000----23,708,000-------
EBT Margin15.9%-1.59-1.89-2.18-2.39-2.45-2.18-2.15-2.04-2.110.240.280.32---------
Net Income-22.7%-82,018,000-66,869,000-69,833,000-88,015,000-84,384,000-76,971,000-71,394,000-81,499,000-69,329,00016,542,000-41,001,000-87,435,00074,935,000-23,708,000-23,086,0001,262,000-91,000-29,123,000-24,596,000-30,324,000-30,799,000
Net Income Margin16.1%-1.53-1.82-2.18-2.39-2.45-2.18-1.47-1.30-1.39-0.30-0.73-0.64---------
Free Cashflow9.7%-59,584,000-66,011,000-44,009,000-98,412,000-65,470,000-67,242,000-64,582,000-82,667,000-34,550,000-41,775,000-17,281,000-23,505,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-8.0%1,7461,8981,8481,8961,7671,8191,8761,9372,0072,0341,2461,253414300214235148146171186170
  Current Assets-15.9%7428829369818529149701,0291,1011,1301,1891,19635624015117081.0077.0099.00113132
    Cash Equivalents-53.3%18038620935432530431042946142546093286.0069.0043.0069.0034.0033.0030.0038.0034.00
  Inventory-17.0%57.0068.0068.0062.0050.0043.0036.0030.0025.0018.0018.0016.0014.0016.0017.0016.0013.0015.0017.0020.0018.00
  Net PPE-9.7%36.0040.0040.0041.0042.0039.0038.0036.0033.0031.0025.0024.0025.0027.0028.0029.0030.0032.0033.0034.0034.00
  Goodwill-0.3%462464410410410410410410410391-----------
Liabilities-7.9%1,0451,1351,2061,2041,2041,1921,1941,2021,2161,19398897278.0017117217493.0095.0095.0091.0056.00
  Current Liabilities-48.3%95.0018427126626382.0084.0061.0072.0056.0045.0034.0039.0013013113249.0051.0049.0045.0027.00
Shareholder's Equity-8.2%70176464269256362768273579184125828133512941.0060.0055.0051.0076.0095.00114
  Retained Earnings-4.7%-1,839-1,757-1,690-1,620-1,532-1,447-1,370-1,299-1,218-1,148-1,165-1,124-1,036-1,111-1,088-1,065-1,066-1,066-1,037-1,012-982
  Additional Paid-In Capital0.7%2,5402,5222,3352,3142,1002,0812,0582,0382,0101,9891,4231,4051,3721,2411,1291,1251,1211,1171,1131,1071,096
Shares Outstanding3.6%268258250250227225223222204202197195---------
Float---3,324---992---6,791---499---855--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations11.7%-57,560-65,181-41,741-94,691-60,566-63,053-60,563-79,029-31,708-40,656-15,712-23,104-14,263-17,808-23,78975,363-18,180-17,260-17,559-25,313-18,985
  Share Based Compensation-15.8%16,58419,69117,89117,95217,95518,93619,01922,70329,564-23,00010,1657,9881,7001,1004,0326,5451,4001,4004,38112,588
Cashflow From Investing-127.5%-66,575242,323-98,591-72,55380,40353,908-60,28142,05365,753-291,646-460,8088,170-98,495-63,641-2,859-54,327-3,40819,6597,81237,984-5,513
Cashflow From Financing-10348.4%-81,602-781-4,715195,9898193,1334555,2151,324299,6562,880865,721125,877107,13562818,19918,1313271,4006,6905,279

PACB Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue:   
Total revenue$ 200,521$ 128,304$ 130,513
Cost of Revenue:   
Amortization of acquired intangible assets1,983733306
Loss on purchase commitment3,4363,7050
Total cost of revenue147,74179,26971,653
Gross profit52,78049,03558,860
Operating Expense:   
Research and development187,170193,000112,899
Sales, general and administrative169,818160,854124,124
Merger-related expenses9,042031,129
Change in fair value of contingent consideration15,0602,3771,143
Amortization of acquired intangible assets6,15700
Total operating expense387,247356,231269,295
Operating loss(334,467)(307,196)(210,435)
Loss from Continuation Advances from Illumina00(52,000)
Loss on extinguishment of debt(2,033)00
Interest expense(14,343)(14,690)(12,530)
Other income, net32,6847,63893
Loss before benefit from income taxes(318,159)(314,248)(274,872)
Benefit from income taxes(11,424)0(93,649)
Net loss(306,735)(314,248)(181,223)
Other comprehensive income (loss):   
Unrealized gain (loss) on investments4,984(3,678)(1,172)
Comprehensive loss$ (301,751)$ (317,926)$ (182,395)
Net loss per share:   
Basic (in usd per share)$ (1.21)$ (1.40)$ (0.89)
Diluted (in usd per share)$ (1.21)$ (1.40)$ (0.89)
Earnings Per Share, Basic, Other Disclosure [Abstract]   
Basic (in shares)253,629224,550204,136
Diluted (in shares)253,629224,550204,136
Product revenue   
Revenue:   
Total revenue$ 183,872$ 108,699$ 113,505
Cost of Revenue:   
Cost of product revenue127,56860,93256,358
Service and other revenue   
Revenue:   
Total revenue16,64919,60517,008
Cost of Revenue:   
Cost of service and other revenue$ 14,754$ 13,899$ 14,989

PACB Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 179,911$ 325,089
Investments451,505447,229
Accounts receivable, net36,61518,786
Inventory, net56,67650,381
Prepaid expenses and other current assets17,04010,289
Short-term restricted cash300300
Total current assets742,047852,074
Property and equipment, net36,43241,580
Operating lease right-of-use assets, net32,59339,763
Long-term restricted cash2,4222,922
Intangible assets, net456,984410,245
Goodwill462,261409,974
Other long-term assets13,27410,528
Total assets1,746,0131,767,086
Current liabilities  
Accounts payable15,06212,028
Accrued expenses45,70832,596
Deferred revenue, current16,34230,498
Operating lease liabilities, current9,5918,886
Other liabilities, current8,3267,233
Contingent consideration liability, current0172,094
Total current liabilities95,029263,335
Deferred revenue, non-current5,5301,794
Contingent consideration liability, non-current19,5500
Operating lease liabilities, non-current31,60641,070
Convertible senior notes, net, non-current892,243896,683
Other liabilities, non-current7511,300
Total liabilities1,044,7091,204,182
Commitments and contingencies
Stockholders’ equity  
Authorized 50,000 shares; No shares issued or outstanding00
Authorized 1,000,000 shares; issued and outstanding 267,744 and 226,505 shares at December 31, 2023 and December 31, 2022, respectively268227
Additional paid-in capital2,539,8922,099,782
Accumulated other comprehensive income (loss)219(4,765)
Accumulated deficit(1,839,075)(1,532,340)
Total stockholders’ equity701,304562,904
Total liabilities and stockholders’ equity$ 1,746,013$ 1,767,086
PACB
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
 CEO
 WEBSITEpacb.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES769

Pacific Biosciences of California Frequently Asked Questions


What is the ticker symbol for Pacific Biosciences of California? What does PACB stand for in stocks?

PACB is the stock ticker symbol of Pacific Biosciences of California. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pacific Biosciences of California (PACB)?

As of Thu Apr 11 2024, market cap of Pacific Biosciences of California is 905.68 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PACB stock?

You can check PACB's fair value in chart for subscribers.

What is the fair value of PACB stock?

You can check PACB's fair value in chart for subscribers. The fair value of Pacific Biosciences of California is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pacific Biosciences of California is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PACB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pacific Biosciences of California a good stock to buy?

The fair value guage provides a quick view whether PACB is over valued or under valued. Whether Pacific Biosciences of California is cheap or expensive depends on the assumptions which impact Pacific Biosciences of California's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PACB.

What is Pacific Biosciences of California's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 11 2024, PACB's PE ratio (Price to Earnings) is -2.95 and Price to Sales (PS) ratio is 4.52. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PACB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Pacific Biosciences of California's stock?

In the past 10 years, Pacific Biosciences of California has provided -0.021 (multiply by 100 for percentage) rate of return.